サンプル依頼リスト カート
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：細胞治療および遺伝子治療市場：取引分析（2021年～2024年）
市場調査レポート
商品コード
1483204

細胞治療および遺伝子治療市場：取引分析（2021年～2024年）

Cell and Gene Therapy Deals Analysis, 2021-2024

出版日
ページ情報
英文 345 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
細胞治療および遺伝子治療市場：取引分析（2021年～2024年）
出版日: 2024年06月03日
発行: Kalorama Information
ページ情報: 英文 345 Pages
納期: 即日から翌営業日
GIIご利用のメリット
担当者のコメント
1,500社を超える企業が細胞・遺伝子治療分野におけるGlobal市場に積極的に参入しており、その動向と競争環境を理解することは戦略立案にとって極めて重要です。当レポートでは、2021年から2024年の4年間における細胞治療および遺伝子治療における各社のディールに着目し、ファイナンス, パートナリング, M&A, 技術移転, IPOs/SPACs,その他ディールをUSDの金額規模で可視化し、これから参入する企業、既に参入している企業双方にとって必要不可欠な市場分析を347ページの内容で提供します。
  • 全表示
  • 概要
  • 目次
概要

当レポートは、細胞治療および遺伝子治療市場について調査し、ダイナミックで急速に進化する細胞治療および遺伝子治療市場を包括的に考察しています。2021年第1四半期から2024年第1四半期までに行われた重要な取引に焦点を当て、この急成長分野を形成する動向を理解し、活用しようとする企業や利害関係者に貴重な洞察を提供します。

目次

第1章 エグゼクティブサマリー

第2章 ベンチャーキャピタルと民間資金調達

  • 流動的なVC/民間資金調達

第3章 戦略的投資

  • 細胞治療および遺伝子治療への戦略的投資

第4章 IPO、FPO、SPAC

  • 北米ではIPO、FPO、SPAC別収益が大部分を占める

第5章 合併と買収（M&A）

  • 平均価値の低下にもかかわらず、M&A件数は増加

第6章 技術/調査/戦略的コラボレーション

  • CGT市場では多様なコラボレーションが見られる

第7章 ライセンシング

  • 細胞治療および遺伝子治療市場におけるライセンシングの安定レベル

第8章 製造とサプライチェーン

  • CGTにおける製造およびサプライチェーン管理活動の大幅な成長

第9章 流通と共同マーケティング

  • CGT販売および共同マーケティング契約の概要

第10章 その他-JV、再編、解散、スピンオフ

  • 細胞治療および遺伝子治療に影響を与える他の種類の取引について
目次
Product Code: 24-022

"Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024" is published in two installments, the first in Q2 2024 and the second in Q4 2024. Customers who purchase the report will receive both installments.

Kalorama Information's "Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024" offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and stakeholders looking to understand and leverage the trends shaping this burgeoning field.

No report published by a major market research publisher has tackled the cell and gene therapy dealmaking space more comprehensively. With cell and gene therapy is becoming a highly competitive marketplace, over a thousand companies are specifically referenced in this report.

Why This Report?

With over 1,500 companies actively involved in the cell and gene therapy space, understanding the trends and competitive landscape is crucial for strategic planning. "Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024" provides the essential market analysis needed to navigate and capitalize on the opportunities within this fast-growing industry.

Report Highlights:

  • Quarterly Funding Trends (Q1 2021-Q1 2024): Graphical representation of funding amounts, showcasing investment influx in cell and gene therapy.
  • Deal Types: Comprehensive categorization of 2000+ deals, including venture capital, private investments, mergers, acquisitions, strategic collaborations, licensing, manufacturing/ supply, and distribution/ co-marketing.
  • Top Deal-Makers: Identification of the most active companies by deal type and overall deal activity.
  • Regional Deal Breakdown: Percentage analysis of deal-making activities across different regions.

Who Should Buy This Report

Understanding the volumes of deals that have been made, who is making which type and how many, and the deals' details, is critical to finding how to take advantage of the opportunities in one of the fastest-growing markets.

Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 is designed to provide companies entering or already in this market with knowledge of the trends in deals that will shape future growth and competition.

The following is just some of the information in this report:

  • Quarterly Funding Amounts Q1 2021- Q1 2024 by Type and Region
  • Specific details of 2000+ CGT Deals
  • Venture Capital/Private Funding Round Amounts, By Quarter
  • Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)
  • Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
  • Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)
  • Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)

Methodology

The report's insights are derived from a blend of primary and secondary research, including interviews with industry professionals, comprehensive literature reviews, and analysis of company and government reports.

Table of Contents

Chapter 1: Executive Summary

  • Introduction
  • $35 Billion in Investment in 2023
    • Figure 1-1: Total Deals per Month, April 2021-April 2024 (count)
    • Figure 1-2: Total Deals per Month, by Type [VC/ Private, IPO/FPO/SPAC; and All Other Deals], April 2021-April 2024 (count)
  • Quarterly Funding Amounts
    • Table 1-1: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], Q1 2024 (in millions $)
    • Table 1-2: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2023 (in millions $)
    • Table 1-3: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2022 (in millions $)
    • Table 1-4: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021 (in millions $)
    • Table 1-5: Total Quarterly Funding, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021-Q1 2024 (in millions $)
    • Figure 1-3: Total Quarterly Funding, Q1 2021- Q1 2024 (in millions $)
    • Figure 1-4: Total Quarterly Funding, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], Q1 2021-Q1 2024 (in millions $)
  • Quarterly Funding Category Shares, Q1 2021 Through Q1 2024
    • Table 1-6: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2023 (%)
    • Table 1-7: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2022
    • Table 1-8: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021 (%)
    • Table 1-9: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021-Q1 2024 (%)
    • Figure 1-5: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], Q1 2021-Q1 2024 (%)
    • Figure 1-6: January-April 2024 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-7: 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-8: 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-9: 2021 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Quarterly Deal Counts by Category, Q1 2021 - Q1 2024
    • Table 1-10: Quarterly Count of Deals, Q1 2024, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal] (total number) (%)
    • Table 1-11: Quarterly Count of Deals, By 2023 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal] (total number) (%)
    • Table 1-12: Quarterly Count of Deals, by 2022 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture] (total number) (%)
    • Table 1-13: Quarterly Count of Deals, by 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture] (total number) (%)
    • Table 1-14: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], 2021-2024 partial (%)
  • Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy
    • Figure 1-10a: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain], 2021-2024 partial (%)
    • Figure 1-10b: Yearly Shares of Number of Deals, By Category [Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], 2021-2024 partial (%)
    • Figure 1-11: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain], Q1 2021-Q1 2024 (Total number)
  • A Look at Less Frequent CGT Deal Types
    • Figure 1-12: Lower Frequency Deal Types, by Quarter, by Category [Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], Q1 2021-Q1 2024 (total number)
    • Figure 1-13: Merger/Acquisition Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 1-14: Venture Capital/Private Funding Round Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 1-15: IPO/FPO Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 1-16: SPAC Portion Amount, by Year, 2021-2023 (in millions $)
  • Most Active Companies
    • Table 1-15: Most Active Companies in CGT Deals, Collaborations, Overall 2021-April 2024
    • Figure 1-17: Most Active Companies in CGT Deals, Collaborations, Overall 2021-April 2024

Chapter 2: Venture Capital & Private Funding

  • VC/Private Funding in Flux
    • Figure 2-1: Total Number of Private Funding/VC Rounds, by Month, Jan 2021-April 2024 (count)
    • Figure 2-2: Average Private Funding/VC Round Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 2-1: Regional Venture Capital/Private Funding, by Region [North America, Europe, APAC, Rest of World], by Quarter Q1 2021-Q1 2024 (in millions $) (%)
    • Figure 2-3: Quarterly Venture Capital/Private Total Funding, by Region [North America, Europe, APAC, Rest of World], Q1 2021-Q1 2024 (in millions $)
    • Table 2-2: Regional Venture Capital/Private Funding Shares, by Region [North America, Europe, APAC, Rest of World], by Quarter Q1 2021-Q1 2024 (%)
    • Figure 2-4: Regional Venture Capital/Private Funding Shares, by Region [North America, Europe, APAC, Rest of World], by Quarter, Q1 2021-Q1 2024, (%)
    • Figure 2-5: Venture Capital/Private Funding Round Amounts, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 2-6: Scaled Venture Capital/Private Funding Round Amounts, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 2-3: Venture Capital/Private Fundraising Deals, Q1 2024
    • Table 2-4: Venture Capital/Private Fundraising Deals, Q4 2023
    • Table 2-5: Venture Capital/Private Fundraising Deals, Q3 2023
    • Table 2-6: Venture Capital/Private Fundraising Deals, Q2 2023
    • Table 2-7: Venture Capital/Private, Q1 2023
    • Table 2-8: Venture Capital/Private Fundraising Deals, Q4 2022
    • Table 2-9: Venture Capital/Private Fundraising Deals, Q3 2022
    • Table 2-10: Venture Capital/Private, Q2 2022
    • Table 2-11: Venture Capital/Private, Q1 2022

Chapter 3: Strategic Investments

  • Strategic Investments in Cell and Gene Therapy
    • Figure 3-1: Total Number of Strategic Investments, By Quarter, Q1 2021-Q1 2024 (count)
    • Figure 3-2: Average Strategic Investment Amount, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 3-3: Total Strategic Investment Amount, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 3-1: Strategic Investment Total Amounts, Counts, and Averages, by Quarter, Q1 2021-Q1 2024, (in millions $)
    • Table 3-2: Strategic Investments, January 2021-April 2024
    • Table 3-3: Most Active in Acquisition/Merger/Strategic Investment, 2021-April 2024
    • Figure 3-4: Most Active in Acquisition/Merger/Strategic Investment, 2021-April 2024

Chapter 4: IPOs, FPOs, & SPACs

  • North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
    • Figure 4-1: Total Number of IPOs/ FPOs, By Month, January 2021-April 2024 (count)
    • Figure 4-2: Average IPO/ FPO Proceeds, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 4-1: Quarterly IPO/ FPO Total Funding, by Region [North America, Europe, APAC], Q1 2021-Q1 2024 (in millions $)
    • Figure 4-3: Total IPO/FPO Funding, by Quarter, by Region [North America, Europe, APAC], Q1 2021-Q1 2024 (in millions $)
    • Table 4-2: Regional IPO/FPO Funding Shares, by Quarter [North America, Europe, APAC], Q1 2021-Q1 2024 (%)
    • Figure 4-4: Regional IPO/FPO Funding Shares, By Quarter, Q1 2021-Q1 2024 [North America, APAC, and Europe) (%)
    • Figure 4-5: IPO/FPO Amounts, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 4-3: Quarterly SPAC Funding Portion, Q1 2021-Q1 2024 (in millions $)
    • Figure 4-6: Quarterly SPAC Funding Portion Total and Average, Q1 2021-Q1 2024 (in millions $)
    • Table 4-4: IPO/FPO Deals, January -May 2024 (in millions $)
    • Table 4-5: IPO/FPO Deals, Q4 2023 (in millions $)
    • Table 4-6: IPO/FPO Deals, Q3 2023 (in millions $)
    • Table 4-7: IPO/FPO Deals, Q2 2023 (in millions $)
    • Table 4-8: IPO/FPO Deals, Q1 2023 (in millions $)
    • Table 4-9: IPO/FPO Deals, Q4 2022 (in millions $)
    • Table 4-10: IPO/FPO Deals, Q3 2022 (in millions $)
    • Table 4-11: IPO/FPO Deals, Q2 2022 (in millions $)
    • Table 4-12: IPO/FPO Deals, Q1 2022 (in millions $)
    • Table 4-13: SPAC Portion, Q1 2021-Q1 2024 (in millions $)
    • Figure 4-7: SPAC Portion Amount, by Year, 2021-2023 (in millions $)

Chapter 5: Mergers & Acquisitions (M&A)

  • Growing Numbers of M&A, Despite Lower Average Value
    • Figure 5-1: Total Number of Mergers and Acquisitions, by Month, January 2021-April 2024 (count)
    • Figure 5-2: Average Merger/Acquisition Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 5-1: Quarterly Merger and Acquisition Values, Counts, and Averages, Q1 2021-Q1 2024 (in millions $) (Total count)
    • Figure 5-3: Merger/ Acquisition Transactions Global Total, By Quarter [Q1 2022- Q1 2024] (in millions $)
    • Figure 5-4: Merger/Acquisition Amounts, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 5-2: Mergers and Acquisitions Announcements, January-May 2024 (in millions $)
    • Table 5-3: Mergers and Acquisitions Announcements, Q4 2023 (in millions $)
    • Table 5-4: Mergers and Acquisitions Announcements, Q3 2023 (in millions $)
    • Table 5-5: Mergers and Acquisitions Announcements, Q2 2023 (in millions $)
    • Table 5-6: Mergers and Acquisitions Announcements, Q1 2023 (in millions $)
    • Table 5-7: Mergers and Acquisitions, Q4 2022 (in millions $)
    • Table 5-8: Mergers and Acquisitions, Q3 2022 (in millions $)
    • Table 5-9: Mergers and Acquisitions, Q2 2022 (in millions $)
    • Table 5-10: Mergers and Acquisitions, Q1 2022 (in millions $)
    • Table 5-11: Most Active in Acquisition/Merger/ Strategic Investment, 2021-April 2024 (count)
    • Figure 5-5: Most Active in Acquisition/Merger/Strategic Investment, 2021-April 2024

Chapter 6: Technology/Research/Strategic Collaborations

  • CGT Market Sees a Broad Variety of Collaborations
    • Figure 6-1: Total Number of Tech/Research/Strategic Collaborations, By Month, January 2021-April 2024 (count)
    • Figure 6-2: Total Number of Collaborations with Upfront and/or Milestone Payments, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 6-1: Collaboration Upfront and Future/Milestone Payments, Counts, Averages, Q1 2021-Q1 2024 (in millions $) (count)
    • Figure 6-3: Average Collaboration Upfront Payment, By Quarter, Q2 2021-Q1 2024 (in millions $)
    • Figure 6-4: Research Collaboration Upfront Payments Total, By Quarter, Q2 2021-Q1 2024 (in millions $)
    • Figure 6-5: Average Collaboration Future/Milestone Payments, By Quarter, Q2 2021-Q1 2024 (in millions $)
    • Figure 6-6: Total Collaboration Future/ Milestone Payments, By Quarter, Q2 2021-Q1 2024 (in millions $)
    • Table 6-2: Technology/Research/Strategic Collaboration Deals, January-May 2024
    • Table 6-3: Technology/Research/Strategic Collaboration Deals, Q4 2023
    • Table 6-4: Technology/Research/Strategic Collaboration Deals, Q3 2023
    • Table 6-5: Technology/Research/Strategic Collaboration Deals, Q2 2023
    • Table 6-6: Technology/Research/Strategic Collaboration Deals, Q1 2022-Q1 2023
    • Table 6-7: Most Active in Research/Strategic Collaborations, 2021-April 2024 (count)
    • Figure 6-7: Most Active in Research/ Strategic Collaborations, 2021-April 2024 (count)

Chapter 7: Licensing

  • Stable Levels of Licensing in the Cell and Gene Therapy Market
    • Figure 7-1: Total Number of Licensing Deals, By Month, January 2021-April 2024 (count)
    • Table 7-1: Licensing Deals, January-April 2024
    • Table 7-2: Licensing Deals, Q4 2023
    • Table 7-3: Licensing Deals, Q3 2023
    • Table 7-4: Licensing Deals, Q2 2023
    • Table 7-5: Licensing Deals, Q1 2022-Q1 2023
    • Table 7-6: Most Active Companies in Licensing Deals, 2021-April 2024 (count)
    • Figure 7-2: Most Active Companies in Licensing Deals, 2021-April 2024 (count)

Chapter 8: Manufacturing and Supply Chain

  • Major Growth in Manufacturing and Supply Chain Management Activity in CGT
    • Figure 8-1: Total Number of Supply/Manufacturing Deals, By Month, January 2021-April 2024 (count)
    • Table 8-1: Manufacturing and Supply Chain Deals, January-May 2024
    • Table 8-2: Manufacturing and Supply Chain Deals, Q4 2023
    • Table 8-3: Manufacturing and Supply Chain Deals, Q3 2023
    • Table 8-4: Manufacturing and Supply Chain Deals, Q2 2023
    • Table 8-5: Manufacturing and Supply Chain Deals, Q1 2022-Q1 2023
    • Table 8-6: Most Active Companies in Manufacturing/Supply Deals, 2021-April 2024 (count)
    • Figure 8-2: Most Active Companies in Manufacturing/Supply Deals, 2021-April 2024 (count)

Chapter 9: Distribution & Co-Marketing

  • A Look at CGT Distribution and Co-Marketing Deals
    • Figure 9-1: Total Number of Distribution/ Co-Marketing Deals, by Month, January 2021-April 2024 (count)
    • Table 9-1: Distribution & Co-Marketing Deals, January-May 2024
    • Table 9-2: Distribution & Co-Marketing Deals, Q4 2023
    • Table 9-3: Distribution & Co-Marketing Deals, Q3 2023
    • Table 9-4: Distribution & Co-Marketing Deals, Q2 2023
    • Table 9-5: Distribution & Co-Marketing Deals, Q1 2022-Q1 2024
    • Table 9-6: Most Active Companies in Manufacturing/ Supply Deals, 2021-April 2024 (count)
    • Figure 9-2: Most Active Companies in Manufacturing/ Supply Deals, 2021-April 2024 (count)

Chapter 10: Other - JV, Restructuring, Termination, Spinoffs

  • A Look at Other Types of Deals Impacting Cell and Gene Therapy
    • Figure 10-1: Total Number of JV, Restructuring, Termination, By Month [January 2021-April 2024 ] (Total count)
    • Table 10-1: Restructuring, JV, Termination, Spinoffs, January 2022-April 2024